{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:39:43Z","timestamp":1770478783372,"version":"3.49.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor disorder characterized by the growth of hamartomas in various organs including the kidney, brain, skin, lungs, and heart. Rapamycin has been shown to reduce the size of kidney angiomyolipomas associated with TSC; however, tumor regression is incomplete and kidney angiomyolipomas regrow after cessation of treatment. Mouse models of <jats:italic>TSC2<\/jats:italic> related tumors are useful for evaluating new approaches to drug therapy for TSC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In cohorts of <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mice, we compared kidney cystadenoma severity in A\/J and C57BL\/6 mouse strains at both 9 and 12 months of age. We also investigated age related kidney tumor progression and compared three different rapamycin treatment schedules in cohorts of A\/J <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mice. In addition, we used nude mice bearing <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>-\/-<\/jats:sup> subcutaneous tumors to evaluate the therapeutic utility of sunitinib, bevacizumab, vincristine, and asparaginase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>TSC related kidney disease severity is 5-10 fold higher in A\/J <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mice compared with C57BL\/6 <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mice. Similar to kidney angiomyolipomas associated with TSC, the severity of kidney cystadenomas increases with age in A\/J <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mice. When rapamycin dosing schedules were compared in A\/J <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> cohorts, we observed a 66% reduction in kidney tumor burden in mice treated daily for 4 weeks, an 82% reduction in mice treated daily for 4 weeks followed by weekly for 8 weeks, and an 81% reduction in mice treated weekly for 12 weeks. In the <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>-\/-<\/jats:sup> subcutaneous tumor mouse model, vincristine is not effective, but angiogenesis inhibitors (sunitinib and bevacizumab) and asparaginase are effective as single agents. However, these drugs are not as effective as rapamycin in that they increased median survival only by 24-27%, while rapamycin increased median survival by 173%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results indicate that the A\/J <jats:italic>Tsc2<\/jats:italic>\n              <jats:sup>+\/-<\/jats:sup> mouse model is an improved, higher through-put mouse model for future TSC preclinical studies. The rapamycin dosing comparison study indicates that the duration of rapamycin treatment is more important than dose intensity. We also found that angiogenesis inhibitors and asparaginase reduce tumor growth in a TSC2 tumor mouse model and although these drugs are not as effective as rapamycin, these drug classes may have some therapeutic potential in the treatment of TSC related tumors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-8-14","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T19:14:41Z","timestamp":1265829281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Comparison of three rapamycin dosing schedules in A\/J Tsc2+\/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors"],"prefix":"10.1186","volume":"8","author":[{"given":"Chelsey","family":"Woodrum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Nobil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra L","family":"Dabora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,10]]},"reference":[{"key":"436_CR1","volume-title":"The tuberous sclerosis complex","year":"1999","unstructured":"Gomez M, Sampson J, Whittemore V, eds: The tuberous sclerosis complex. 1999, Oxford University Press: Oxford, England, Third","edition":"Third"},{"issue":"13","key":"436_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355 (13): 1345-56. 10.1056\/NEJMra055323.","journal-title":"N Engl J Med"},{"issue":"1","key":"436_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ: Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs. Am J Hum Genet. 2001, 68 (1): 64-80. 10.1086\/316951.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"436_CR4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1086\/342718","volume":"71","author":"SL Dabora","year":"2002","unstructured":"Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, Kwiatkowski DJ: Association between a High-Expressing Interferon-gamma Allele and a Lower Frequency of Kidney Angiomyolipomas in TSC2 Patients. Am J Hum Genet. 2002, 71 (4): 750-758. 10.1086\/342718.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"436_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0022-5347(01)63072-6","volume":"160","author":"DH Ewalt","year":"1998","unstructured":"Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES: Renal lesion growth in children with tuberous sclerosis complex. J Urol. 1998, 160 (1): 141-5. 10.1016\/S0022-5347(01)63072-6.","journal-title":"J Urol"},{"issue":"4","key":"436_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1165\/rcmb.2006-0372TR","volume":"36","author":"SC Juvet","year":"2007","unstructured":"Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP: Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol. 2007, 36 (4): 398-408. 10.1165\/rcmb.2006-0372TR.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"436_CR7","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","volume":"97","author":"T Carsillo","year":"2000","unstructured":"Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000, 97 (11): 6085-90. 10.1073\/pnas.97.11.6085.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"436_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"ECTS Consortium","year":"1993","unstructured":"Consortium ECTS: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993, 75 (7): 1305-15.","journal-title":"Cell"},{"issue":"5327","key":"436_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, Ouweland van den A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997, 277 (5327): 805-8. 10.1126\/science.277.5327.805.","journal-title":"Science"},{"issue":"11","key":"436_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1101\/gad.901101","volume":"15","author":"X Gao","year":"2001","unstructured":"Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001, 15 (11): 1383-92. 10.1101\/gad.901101.","journal-title":"Genes Dev"},{"issue":"3","key":"436_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0092-8674(01)00333-6","volume":"105","author":"CJ Potter","year":"2001","unstructured":"Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell. 2001, 105 (3): 357-68. 10.1016\/S0092-8674(01)00333-6.","journal-title":"Cell"},{"issue":"3","key":"436_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell. 2006, 124 (3): 471-84. 10.1016\/j.cell.2006.01.016.","journal-title":"Cell"},{"issue":"41","key":"436_CR13","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008, 27 (41): 5497-510. 10.1038\/onc.2008.245.","journal-title":"Oncogene"},{"issue":"10","key":"436_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","volume":"13","author":"GG Chiang","year":"2007","unstructured":"Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007, 13 (10): 433-42. 10.1016\/j.molmed.2007.08.001.","journal-title":"Trends Mol Med"},{"issue":"1","key":"436_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.gde.2004.11.002","volume":"15","author":"GM Findlay","year":"2005","unstructured":"Findlay GM, Harrington LS, Lamb RF: TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation?. Curr Opin Genet Dev. 2005, 15 (1): 69-76. 10.1016\/j.gde.2004.11.002.","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"436_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang J, Manning BD: The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008, 412 (2): 179-90. 10.1042\/BJ20080281.","journal-title":"Biochem J"},{"issue":"15","key":"436_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & Development. 2003, 17 (15): 1829-34.","journal-title":"Genes & Development"},{"issue":"2","key":"436_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/GIM.0b013e31803068c7","volume":"9","author":"KS Au","year":"2007","unstructured":"Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, Wheless JW, Baumgartner JE, Roa BB, Wilson CM, Smith-Knuppel TK, Cheung MY, Whittemore VH, King TM, Northrup H: Genotype\/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007, 9 (2): 88-100. 10.1097\/GIM.0b013e31803068c7.","journal-title":"Genet Med"},{"issue":"6","key":"436_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","volume":"13","author":"O Sancak","year":"2005","unstructured":"Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, Ouweland van den A: Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005, 13 (6): 731-41. 10.1038\/sj.ejhg.5201402.","journal-title":"Eur J Hum Genet"},{"key":"436_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2210-7-14","volume":"7","author":"MP Messina","year":"2007","unstructured":"Messina MP, Rauktys A, Lee L, Dabora SL: Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol. 2007, 7: 14-10.1186\/1471-2210-7-14.","journal-title":"BMC Pharmacol"},{"issue":"3","key":"436_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer. 2005, 42 (3): 213-27. 10.1002\/gcc.20118.","journal-title":"Genes Chromosomes Cancer"},{"issue":"9366","key":"436_CR22","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","volume":"361","author":"N El-Hashemite","year":"2003","unstructured":"El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ: Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 2003, 361 (9366): 1348-9. 10.1016\/S0140-6736(03)13044-9.","journal-title":"Lancet"},{"issue":"12","key":"436_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/jnen\/63.12.1236","volume":"63","author":"JA Chan","year":"2004","unstructured":"Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ: Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 2004, 63 (12): 1236-42.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"436_CR24","first-page":"400","volume":"59","author":"EP Henske","year":"1996","unstructured":"Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996, 59 (2): 400-6.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"436_CR25","first-page":"1639","volume":"151","author":"EP Henske","year":"1997","unstructured":"Henske EP, Wessner LL, Golden J, Scheithauer BW, Vortmeyer AO, Zhuang Z, Klein-Szanto AJ, Kwiatkowski DJ, Yeung RS: Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol. 1997, 151 (6): 1639-47.","journal-title":"Am J Pathol"},{"issue":"56","key":"436_CR26","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"19","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000, 19 (56): 6680-6. 10.1038\/sj.onc.1204091.","journal-title":"Oncogene"},{"issue":"22","key":"436_CR27","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, T O'Toole, Lustgarten S, Moore L, Motzer RJ: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007, 356 (22): 2271-81. 10.1056\/NEJMoa066838.","journal-title":"N Engl J Med"},{"issue":"9637","key":"436_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372 (9637): 449-56. 10.1016\/S0140-6736(08)61039-9.","journal-title":"Lancet"},{"issue":"3","key":"436_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1006\/bbrc.2000.3071","volume":"273","author":"S Ikeda","year":"2000","unstructured":"Ikeda S, Mochizuki A, Sarker AH, Seki S: Identification of functional elements in the bidirectional promoter of the mouse Nthl1 and Tsc2 genes. Biochem Biophys Res Commun. 2000, 273 (3): 1063-8. 10.1006\/bbrc.2000.3071.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"436_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","volume":"57","author":"H Kenerson","year":"2005","unstructured":"Kenerson H, Dundon TA, Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005, 57 (1): 67-75. 10.1203\/01.PDR.0000147727.78571.07.","journal-title":"Pediatr Res"},{"issue":"10","key":"436_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/gcc.20357","volume":"45","author":"L Lee","year":"2006","unstructured":"Lee L, Sudentas P, Dabora SL: Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer. 2006, 45 (10): 933-44. 10.1002\/gcc.20357.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"436_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006, 59 (3): 490-8. 10.1002\/ana.20784.","journal-title":"Ann Neurol"},{"issue":"2","key":"436_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1056\/NEJMc072500","volume":"358","author":"DM Davies","year":"2008","unstructured":"Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 200-3. 10.1056\/NEJMc072500.","journal-title":"N Engl J Med"},{"issue":"2","key":"436_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 140-51. 10.1056\/NEJMoa063564.","journal-title":"N Engl J Med"},{"issue":"48","key":"436_CR35","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1038\/sj.onc.1209882","volume":"25","author":"J Avruch","year":"2006","unstructured":"Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K: Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene. 2006, 25 (48): 6361-72. 10.1038\/sj.onc.1209882.","journal-title":"Oncogene"},{"issue":"5","key":"436_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001, 97 (5): 1211-8. 10.1182\/blood.V97.5.1211.","journal-title":"Blood"},{"issue":"2","key":"436_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1006\/bbrc.1999.0920","volume":"260","author":"Y Iiboshi","year":"1999","unstructured":"Iiboshi Y, Papst PJ, Hunger SP, Terada N: L-Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun. 1999, 260 (2): 534-9. 10.1006\/bbrc.1999.0920.","journal-title":"Biochem Biophys Res Commun"},{"issue":"42","key":"436_CR38","doi-asserted-by":"publisher","first-page":"31222","DOI":"10.1074\/jbc.M604511200","volume":"281","author":"RB Reinert","year":"2006","unstructured":"Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, McNurlan MA, Wek RC, Anthony TG: Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006, 281 (42): 31222-33. 10.1074\/jbc.M604511200.","journal-title":"J Biol Chem"},{"issue":"3","key":"436_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1067\/mjd.2002.120530","volume":"46","author":"JL Arbiser","year":"2002","unstructured":"Arbiser JL, Brat D, Hunter S, J D'Armiento, Henske EP, Arbiser ZK, Bai X, Goldberg G, Cohen C, Weiss SW: Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002, 46 (3): 376-80. 10.1067\/mjd.2002.120530.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"436_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","volume":"4","author":"JB Brugarolas","year":"2003","unstructured":"Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003, 4 (2): 147-58. 10.1016\/S1535-6108(03)00187-9.","journal-title":"Cancer Cell"},{"issue":"3","key":"436_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","volume":"4","author":"K Seyama","year":"2006","unstructured":"Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y: Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006, 4 (3): 143-52. 10.1089\/lrb.2006.4.143.","journal-title":"Lymphat Res Biol"},{"issue":"2","key":"436_CR42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1056\/NEJMc0707517","volume":"358","author":"LR Young","year":"2008","unstructured":"Young LR, Inoue Y, McCormack FX: Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008, 358 (2): 199-200. 10.1056\/NEJMc0707517.","journal-title":"N Engl J Med"},{"issue":"5","key":"436_CR43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1378\/chest.08-1160","volume":"135","author":"CG Glasgow","year":"2009","unstructured":"Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J: Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009, 135 (5): 1293-300. 10.1378\/chest.08-1160.","journal-title":"Chest"},{"key":"436_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"L Adnane","year":"2006","unstructured":"Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol. 2006, 407: 597-612. 10.1016\/S0076-6879(05)07047-3.","journal-title":"Methods Enzymol"},{"issue":"19","key":"436_CR45","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64 (19): 7099-109. 10.1158\/0008-5472.CAN-04-1443.","journal-title":"Cancer Res"},{"issue":"2","key":"436_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-34. 10.1056\/NEJMoa060655.","journal-title":"N Engl J Med"},{"issue":"26","key":"436_CR47","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006, 24 (26): 4293-300. 10.1200\/JCO.2005.01.3441.","journal-title":"J Clin Oncol"},{"issue":"2","key":"436_CR48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 115-24. 10.1056\/NEJMoa065044.","journal-title":"N Engl J Med"},{"issue":"9544","key":"436_CR49","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368 (9544): 1329-38. 10.1016\/S0140-6736(06)69446-4.","journal-title":"Lancet"},{"issue":"26","key":"436_CR50","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357 (26): 2666-76. 10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"issue":"24","key":"436_CR51","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-50. 10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"issue":"14","key":"436_CR52","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1212\/01.wnl.0000345668.03039.90","volume":"72","author":"PL Nghiemphu","year":"2009","unstructured":"Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009, 72 (14): 1217-22. 10.1212\/01.wnl.0000345668.03039.90.","journal-title":"Neurology"},{"issue":"12","key":"436_CR53","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25 (12): 1539-44. 10.1200\/JCO.2006.09.6305.","journal-title":"J Clin Oncol"},{"issue":"4","key":"436_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004, 7 (4): 335-45. 10.1007\/s10456-004-8272-2.","journal-title":"Angiogenesis"},{"issue":"5","key":"436_CR55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349 (5): 427-34. 10.1056\/NEJMoa021491.","journal-title":"N Engl J Med"},{"issue":"9605","key":"436_CR56","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370 (9605): 2103-11. 10.1016\/S0140-6736(07)61904-7.","journal-title":"Lancet"},{"issue":"10","key":"436_CR57","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1158\/0008-5472.CAN-05-4510","volume":"66","author":"X Jiang","year":"2006","unstructured":"Jiang X, Yeung RS: Regulation of microtubule-dependent protein transport by the TSC2\/mammalian target of rapamycin pathway. Cancer Res. 2006, 66 (10): 5258-69. 10.1158\/0008-5472.CAN-05-4510.","journal-title":"Cancer Res"},{"issue":"8","key":"436_CR58","first-page":"3591","volume":"43","author":"H Mujagic","year":"1983","unstructured":"Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE: Effects of vincristine on cell survival, cell cycle progression, mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res. 1983, 43 (8): 3591-7.","journal-title":"Cancer Res"},{"issue":"10","key":"436_CR59","first-page":"3798","volume":"36","author":"RH Himes","year":"1976","unstructured":"Himes RH, Kersey RN, Heller-Bettinger I, Samson FE: Action of the vinca alkaloids vincristine, vinblastine, desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976, 36 (10): 3798-802.","journal-title":"Cancer Res"},{"issue":"6","key":"436_CR60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI7319","volume":"104","author":"H Onda","year":"1999","unstructured":"Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ: TSC2+\/- mice develop tumors in multiple sites which express gelsolin and are influenced by genetic background. J Clin Invest. 1999, 104 (6): 687-95. 10.1172\/JCI7319.","journal-title":"J Clin Invest"},{"key":"436_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2210-9-8","volume":"9","author":"N Lee","year":"2009","unstructured":"Lee N, Woodrum C, Nobil A, Rauktys A, Messina MP, Dabora SL: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 2009, 9: 8-10.1186\/1471-2210-9-8.","journal-title":"BMC Pharmacol"},{"issue":"4","key":"436_CR62","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1215\/15228517-2007-024","volume":"9","author":"S de Bouard","year":"2007","unstructured":"de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol. 2007, 9 (4): 412-23. 10.1215\/15228517-2007-024.","journal-title":"Neuro Oncol"},{"issue":"11","key":"436_CR63","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-07-0237","volume":"6","author":"H Huynh","year":"2007","unstructured":"Huynh H, Teo CC, Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther. 2007, 6 (11): 2959-66. 10.1158\/1535-7163.MCT-07-0237.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"436_CR64","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2003-08-2911","volume":"103","author":"NL Liem","year":"2004","unstructured":"Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S, Ramirez CD, Rice AM, Haber M, Norris MD, MacKenzie KL, Lock RB: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004, 103 (10): 3905-14. 10.1182\/blood-2003-08-2911.","journal-title":"Blood"},{"issue":"1","key":"436_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-5945-8-1","volume":"8","author":"A Rauktys","year":"2008","unstructured":"Rauktys A, Lee N, Lee L, Dabora SL: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol. 2008, 8 (1): 1-10.1186\/1471-5945-8-1.","journal-title":"BMC Dermatol"},{"key":"436_CR66","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-1-59745-471-1_23","volume":"530","author":"T Doetschman","year":"2009","unstructured":"Doetschman T: Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol. 2009, 530: 423-33. full_text.","journal-title":"Methods Mol Biol"},{"issue":"21","key":"436_CR67","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","volume":"28","author":"L Meikle","year":"2008","unstructured":"Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ: Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008, 28 (21): 5422-32. 10.1523\/JNEUROSCI.0955-08.2008.","journal-title":"J Neurosci"},{"issue":"8","key":"436_CR68","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ: Reversal of learning deficits in a Tsc2+\/- mouse model of tuberous sclerosis. Nat Med. 2008, 14 (8): 843-8. 10.1038\/nm1788.","journal-title":"Nat Med"},{"issue":"4","key":"436_CR69","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.21331","volume":"63","author":"LH Zeng","year":"2008","unstructured":"Zeng LH, Xu L, Gutmann DH, Wong M: Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008, 63 (4): 444-53. 10.1002\/ana.21331.","journal-title":"Ann Neurol"},{"issue":"8","key":"436_CR70","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1073\/pnas.0810790106","volume":"106","author":"JJ Yu","year":"2009","unstructured":"Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP: Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA. 2009, 106 (8): 2635-40. 10.1073\/pnas.0810790106.","journal-title":"Proc Natl Acad Sci USA"},{"key":"436_CR71","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1476-4598-8-38","volume":"8","author":"K Pollizzi","year":"2009","unstructured":"Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D: Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer. 2009, 8: 38-10.1186\/1476-4598-8-38.","journal-title":"Mol Cancer"},{"issue":"6","key":"436_CR72","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/0008-5472.CAN-04-3840","volume":"65","author":"N El-Hashemite","year":"2005","unstructured":"El-Hashemite N, Walker V, Kwiatkowski DJ: Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res. 2005, 65 (6): 2474-81. 10.1158\/0008-5472.CAN-04-3840.","journal-title":"Cancer Res"},{"issue":"6","key":"436_CR73","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2008.01.036","volume":"48","author":"I Lenci","year":"2008","unstructured":"Lenci I, Angelico M, Tisone G, Orlacchio A, Palmieri G, Pinci M, Bombardieri R, Curatolo P: Massive hepatic angiomyolipoma in a young woman with tuberous sclerosis complex: significant clinical improvement during tamoxifen treatment. J Hepatol. 2008, 48 (6): 1026-9. 10.1016\/j.jhep.2008.01.036.","journal-title":"J Hepatol"},{"issue":"7","key":"436_CR74","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1158\/1535-7163.MCT-09-0055","volume":"8","author":"GA Finlay","year":"2009","unstructured":"Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ: Renal and liver tumors in Tsc2+\/- mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther. 2009, 8 (7): 1799-807. 10.1158\/1535-7163.MCT-09-0055.","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-8-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T05:18:36Z","timestamp":1630473516000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-8-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,10]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-8-14","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,10]]},"assertion":[{"value":"30 September 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}